Prelude PRT2527

{ "short_title": "Prelude PRT2527", "data_mode": "900", "data_mode_number": "000002386", "official_title": "A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib or Venetoclax in Participants with Relapsed/Refractory Hematologic Malignancies.", "accrual_state": "planned", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "not_applicable", "therapielinie_value": "not_applicable", "ctgov_number": "NCT05665530", "eudract_number": "2022-502672-23", "general_contact_email": "ectu@ukdd.de", "general_contact_phone": "+49 351-4587566", "hauptpruefer_dd_name": "Prof. Dr. med. habil Martin Wermke", "description_laie_de": "Eine Phase-1-Studie zu PRT2527 als Monotherapie und in Kombination mit Zanubrutinib oder Venetoclax bei Teilnehmern mit rezidiviertem/refrakt\u00e4rem H\u00e4matologikum Malignome.", "description_laie_en": "A Phase 1 Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib or Venetoclax in Participants with Relapsed/Refractory Hematologic \r\nMalignancies.", "description_expert_de": "Eine Phase-1-Studie zu PRT2527 als Monotherapie und in Kombination mit Zanubrutinib oder Venetoclax bei Teilnehmern mit rezidiviertem/refrakt\u00e4rem H\u00e4matologikum Malignome.", "description_expert_en": "A Phase 1 Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib or Venetoclax in Participants with Relapsed/Refractory Hematologic \r\nMalignancies.", "rechtsgrundlage_value": "AMG", "phase_amg_value": "I", "main_cat_id": 4, "sub_cat_id": 30 }